P716: A 2-week course of Exclusive Enteral Nutrition followed by the Crohn Disease Exclusion Diet is effective for Induction and Maintenance of Remission in children with Crohn Disease; the DIETOMICS-CD trialECCO’23 CopenhagenYear: 2023
Authors: Sigall-Boneh, R.(1,2)*;Manuel Navas-López, V.(3); Hussey, S.(4);Pujol Muncunill, G.(5);Lawrence, S.(6);Jonsson Rolandsdotter, H.(7,8);Otley, A.(9);Martín-de-Carpi5, J.(5);Abramas, L.(1);Herrador López , M.(10);Egea Castillo, N.(11);Chen, M.(12);Hurley, M.(13);Wingate, K.(14);Olen, O.(15,16);yaakov, M.(1);Levine, A.(1,17);Van Limbergen, J.(18,19);Wine, E.(12);
(1)The E. Wolfson Medical Center, Paediatric Gastroenterology and Nutrition Unit, Holon, Israel;(2)Tel-Aviv University, The Sackler Faculty of Medicine, Tel Aviv, Israel;(3)Hospital Regional Universitario de Málaga, Paediatric Gastroenterology and Nutrition Unit-, Málaga, Spain;(4)Royal College of Surgeons of Ireland and University College Dublin, National Children's Research Centre, Dublin, Ireland;(5)Hospital Sant Joan de Déu, Paediatric Gastroenterology- Hepatology and Nutrition Department., Barcelona, Spain;(6)BC Children's Hospital- University of British Columbia- BC, Paediatric Gastroenterology, Vancouver-, Canada;(7)Södersjukhuset- Karolinska Institutet- 11883, Department of Clinical Science and Education-, Stockholm, Sweden;(8)Sachs' Children and Youth Hospital- Södersjukhuset- 11883, Department of Gastroenterology, Stockholm-, Sweden;(9)IWK Health Center- - NS B3K 6R8, Division of Gastroenterology and Nutrition-, Halifax, Canada;(10)Hospital Regional Universitario de Málaga, Paediatric Gastroenterology and Nutrition Unit, Málaga, Spain;(11)Hospital Sant Joan de Déu, Paediatric Gastroenterology- Hepatology and Nutrition Department., - Barcelona, Spain;(12)University of Alberta, Departments of Paediatrics and Physiology, Edmonton, Canada;(13)Children's Health Ireland - Crumlin, Children's Health Ireland, Dublin, Ireland;(14)BC Children's Hospital- University of British Columbia - BC, Paediatric gastroenterology, Vancouver, Canada;(15)Sachs' Children and Youth Hospital- Södersjukhuset- 11883, Department of Gastroenterology, Stockholm, Sweden;(16)Karolinska Institutet., Clinical Epidemiology Division- Department of Medicine Solna-, Stockholm, Sweden;(17)Tel Aviv University, 2. The Sackler Faculty of Medicine, Tel Aviv, Israel;(18)Amsterdam University Medical Centers- Emma Children's Hospital, Division of Paediatric Gastroenterology and Nutrition- Department of Pediatrics, Amsterdam, Netherlands Antilles;(19)Tytgat Institute for Liver and Intestinal Research- Academic Medical Center- University of Amsterdam, Amsterdam Gastroenterology Endocrinology and Metabolism, Amsterdam, Netherlands Antilles;
P717: Use of tramadol versus traditional opioids and adverse outcomes of Inflammatory Bowel Diseases: a Danish nationwide cohort studyECCO’23 CopenhagenYear: 2023
Authors: Dalal, R.(1)*;Lund, K.(2);Zegers, F.(2);Friedman, S.(1);Allegretti, J.(1);Norgard, B.(2);
(1)Brigham and Women's Hospital- Harvard Medical School, Gastroenterology- Hepatology and Endoscopy, Boston, United States;(2)Odense University Hospital, Clinical Epidemiology, Odense, Denmark;
P718: A Phase I Study of Ex Vivo Expanded Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Pediatric Perianal Fistulizing Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Otero Piñeiro, A.(1)*; Lightner , A.L.(1);Reese , J.(2);Ream , J.(3);Nachand , D.(4);Adams , A.(5);VanDenBossche, A.(1);Kurowski, J.(6);
(1)Digestive Disease Surgical Institute- Cleveland Clinic, Colorectal Surgery, Cleveland, United States;(2)Cleveland Clinic, National Center for Regenerative Medicine, Cleveland, United States;(3)Digestive Disease Surgical Institute- Cleveland Clinic, Department of Abdominal Radiology-, Cleveland, United States;(4)Digestive Disease Surgical Institute- Cleveland Clinic, Department of Abdominal Radiology, Cleveland, United States;(5)Digestive Disease Surgical Institute- Cleveland Clinic, Department of Colorectal Surgery, Cleveland, United States;(6)Pediatric Institute- Cleveland Clinic, Pediatrics, Cleveland, United States;
P719: Symptomatic improvement and long-term stability of ulcerative colitis symptoms over 3 years of ozanimod treatmentECCO’23 CopenhagenYear: 2023
Authors: Danese, S.(1)*;Abreu, M.T.(2);Afzali, A.(3);Canavan, J.B.(4);Jain, A.(4);Wu, H.(4);Petersen, A.(4);Panaccione, R.(5);Wolf, D.C.(6);
(1)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology, Milan, Italy;(2)University of Miami Miller School of Medicine, Medicine, Miami, United States;(3)University of Cincinnati College of Medicine, Medicine, Cincinnati, United States;(4)Bristol Myers Squibb, Clinical Research, Princeton, United States;(5)Inflammatory Bowel Disease Clinic, Medicine, Calgary, Canada;(6)Atlanta Gastroenterology Associates LLC, Medicine, Atlanta, United States;
P720: Drug survival of first-line biologics in inflammatory bowel disease: large single-centre experience from UR-CAREECCO’23 CopenhagenYear: 2023
Authors: Hanzel, J.(1)*;Supovec, E.(2);Smrekar, N.(1);Koželj, M.(1);Kurent, T.(1);Štabuc, B.(1);Novak, G.(1);Drobne, D.(1);
(1)University Medical Centre Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia;(2)University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia;SING (Slovenian National IBD Study Group)
P722: Symptom-based disease trajectories Identify a population of early super-responders in ulcerative colitis achieving complete disease control under targeted therapyECCO’23 CopenhagenYear: 2023
Authors: Tran, F.(1,2)*;Brard, R.(3);Flechsenhar, K.(4);Aden, K.(1,2);Rosenstiel, P.(2);Agueusop, I.(3);Schreiber, S.(1,2);
(1)University Medical Center Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(2)University Medical Center Schleswig-Holstein, Institute of Clinical Molecular Biology, Kiel, Germany;(3)Sanofi, Biostatistics & Programing- Early Development & Research Statistics, Frankfurt am Main, Germany;(4)Sanofi, Immunology and Inflammation Therapeutic Area- Type 1/17 Immunology Cluster, Frankfurt am Main, Germany;
P723: Comparison of the Persistence Rates of Biologic Agents in Paediatric Crohn's Disease Patients (Japanese Paediatric IBD Registry Study)ECCO’23 CopenhagenYear: 2023
Authors: Nishida, D.(1);Ishige, T.(2);Arai, K.(3);Shimizu, H.(3);Iwama, I.(4);Nambu, R.(4);Kunisaki, R.(1);Yaguchi, K.(1)*;Mizuochi, T.(5);Murakoshi, T.(6);Saito, T.(7);Kato, S.(8);Kudo, T.(9);Iwata, N.(10);Inoue, M.(11);Yodoshi, T.(12);Hagiwara, S.I.(13);Toita, N.(14);Tajiri, H.(15);Mochizuki, T.(16);Kakuta, F.(17);Kumagai, H.(18);Noguchi, A.(19);Sasaki, M.(20);Nishimata, S.(21);Aomatsu, T.(22);Hirano, Y.(3);Shimizu, T.(23);
(1)Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan;(2)Gunma University, Department of Paediatrics, Maebashi, Japan;(3)National Centre for Child Health and Development, Inflammatory Bowel Disease Centre, Tokyo, Japan;(4)Saitama Children's Medical Centre, Division of Gastroenterology and Hepatology, Saitama, Japan;(5)Kurume University, Department of Pediatrics and Child Health, Kurume, Japan;(6)Tokyo Metropolitan Children's Medical Centre, Department of Gastroenterology, Tokyo, Japan;(7)Chiba University, Department of Pediatric Surgery, Chiba, Japan;(8)Shinshu University, Department of Paediatrics, Matsumoto, Japan;(9)Juntendo University, Department of Paediatrics and Adolescent Medicine, Tokyo, Japan;(10)Aichi Children's Health and Medical Centre, Department of Infection and Immunology, Ohobu, Japan;(11)Mie University, Department of Gastrointestinal and Paediatric Surgery, Tsu, Japan;(12)Okinawa Chubu Hospital, Department of Paediatrics, Okinawa, Japan;(13)Osaka Women's and Children's Hospital, Department of Gastroenterology- Nutrition and Endocrinology, Izumi, Japan;(14)Sapporo Kosei General Hospital, Department of Paediatrics, Sapporo, Japan;(15)Osaka General Medical Centre, Department of Paediatrics, Osaka, Japan;(16)Osaka Police Hospital, Department of Pediatrics, Osaka, Japan;(17)Miyagi Children's Hospital, Department of General Paediatrics and Gastroenterology, Sendai, Japan;(18)Jichi Medical University, Department of Pediatrics, Shimotuke, Japan;(19)Akita University, Department of Paediatrics, Akita, Japan;(20)Iwate Medical University, Department of Paediatrics, Morioka, Japan;(21)Tokyo Medical University, Department of Paediatrics, Tokyo, Japan;(22)Osaka Medical University, Department of Paediatrics, Takatsuki, Japan;(23)Juntendo University, Department of Pediatrics and Adolescent Medicine, Tokyo, Japan;
P724: Upadacitinib is Effective and Safe in Tofacitinib-Experienced Patients with Ulcerative Colitis: A Prospective Real-World ExperienceECCO’23 CopenhagenYear: 2023
Authors: Krugliak Cleveland, N.(1)*;Friedberg, S.(1);Choi, D.(1);Hunold, T.(1);Choi, N.K.(1);Garcia, N.M.(1);Picker, E.A.(1);Cohen, N.A.(1);Cohen, R.D.(1);Dalal, S.R.(1);Pekow, J.(1);Sakuraba, A.(1);Rubin, D.T.(1);
(1)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;
P725: Patients with Immune Mediated Inflammatory Diseases are insufficiently protected against vaccine-preventable influenza and pneumococcal infections due to low vaccination ratesECCO’23 CopenhagenYear: 2023
Authors: Van De Pol, N.(1)*;van der Woude, C.J.(1);Vis, M.(2);van Doorn, M.B.A.(3);Derikx, L.A.A.P.(1);Molendijk, I.(1);de Vries, A.C.(1);
(1)Erasmus MC, Gastroenterology and hepatology, Rotterdam, The Netherlands;(2)Erasmus MC, Rheumatology, Rotterdam, The Netherlands;(3)Erasmus MC, Dermatology, Rotterdam, The Netherlands;
P726: Fecal calprotectin and quality of life questionnaires are responsive to change in pouch disease activity following antibiotic therapy—results from a prospective clinical trialECCO’23 CopenhagenYear: 2023
Authors: Ollech, J.(1)*;Yanai, H.(2);Avni Biron, I.(2);Dotan, I.(2);
(1)Rabin Medical Center, Gastroenterology, Petach Tikva, Israel;(2)Rabin Medical Center- Petah-Tikva- Israel- Sackler Faculty of Medicine- Tel Aviv University- Tel Aviv- Israel, Gastroenterology, petah tikva, Israel;
P727: Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational StudiesECCO’23 CopenhagenYear: 2023
Authors: Macaluso, F.S.(1)*;Ventimiglia, M.(2);Orlando, A.(3);
(1)"Villa Sofia-Cervello” Hospital, IBD Unit, Palermo, Italy;(2)Italian Ministry of Health, Directorate General of Medical Device and Pharmaceutical Service- Italian Ministry of Health, Rome, Italy;(3)“Villa Sofia-Cervello” Hospital, IBD Unit, Palermo, Italy;
P729: Evaluation of hepatobiliary pathologies using transient elastography in patients with inflammatory bowel disease: What about the effect of drugs?ECCO’23 CopenhagenYear: 2023
Authors: Ağargün, B.F.(1);Şenkal, İ.V.(2);Rustamzade, A.(2);Nuriyev, K.(2);İstemihan, Z.(2);İmanov, Z.(2);Genç, S.(2);Çelik, B.(3);Şahutoğulları, D.(3);Çavuş, B.(2);Çifcibaşı Örmeci, A.(2);Demir, K.(2);Beşışık, S.F.(2);Kaymakoğlu, S.(2);Akyüz, F.(2)*;
(1)İstanbul Faculty of Medicine- İstanbul University, Department of Internal Medicine, Istanbul, Turkey;(2)İstanbul Faculty of Medicine- İstanbul University, Division of Gastroenterohepatology- Department of Internal Medicine, Istanbul, Turkey;(3)İstanbul Faculty of Medicine- İstanbul University, Faculty of Medicine, Istanbul, Turkey;
P730: Anti tumor necrosis factor treatment in Ulcerative Colitis: Real-world data and evaluation of current treatment targets (STRIDE II)ECCO’23 CopenhagenYear: 2023
Authors: Lundekvam, J.A.(1,2)*;Lie Høivik, M.(1,2);Anisdahl, K.(1,2);Cvancarova Småstuen, M.(3);Medhus, A.W.(1,2);
(1)Oslo University Hospital, Department of Gastroenterology, Oslo, Norway;(2)University of Oslo, Institute of Clinical Medicine, Oslo, Norway;(3)Oslo Metropolitan University, Department of Public Health, Oslo, Norway;Inflammatory Bowel Disease Research Group - Oslo University Hospital
P731: Effect on direct and indirect costs of switching Inflammatory Bowel Disease patients from intravenous to subcutaneous infliximab (CT-P13)ECCO’23 CopenhagenYear: 2023
Authors: Carbery, I.(1)*;Broglio, G.(2);Clark, T.(1);Greer, D.(1);Alakkari, A.(1);Selinger, C.P.(1);
(1)Leeds Teaching Hospitals Trust, Department of Gastroenterology, Leeds, United Kingdom;(2)IRCCS Fondazione Policlinico San Matteo, Internal Medicine, Pavia, Italy;
P732: Impact of different types of physical activity in inflammatory bowel diseaseECCO’23 CopenhagenYear: 2023
Authors: Gofflot, A.(1)*;Monin, L.(2);Seidel, L.(3);Reenaers, C.(2);Kropp, S.(2);Van Kemseke, C.(2);Latour, P.(2);Forthomme, B.(1);Croisier, J.L.(1);Louis, E.(2);Vieujean, S.(2);
(1)University Hospital of Liege, Department of Physical Medicine and Rehabilitation, Liège, Belgium;(2)University Hospital of Liege, Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;(3)University Hospital of Liege, Department of Biostatistics and Medico-economic Information, Liège, Belgium;
P733: Novelties of COVID-19 vaccination beyond efficacy: Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patientsECCO’23 CopenhagenYear: 2023
Authors: Resál, T.(1)*;Horváth, M.(2);Bacsur, P.(1);Szántó, K.(1);Rutka, M.(1);Bálint, A.(1);Fábián, A.(1);Bor, R.(1);Szepes, Z.(1);Fekete, J.(3);Miheller, P.(2);Molnár, T.(1);
(1)Szent-Györgyi Albert Medical School- University of Szeged, Department of Medicine, Szeged, Hungary;(2)Faculty of Medicine- Semmelweis University, Department of Surgery and Interventional Gastroenterology, Budapest, Hungary;(3)Semmelweis University, Department of Bioinformatics, Budapest, Hungary;
P734: A single measurement of fecal calprotectin, particularly if combined with hemoglobin and C-reactive protein levels, predicts Crohn's disease prognosis - a prospective studyECCO’23 CopenhagenYear: 2023
Authors: Magro, F.(1);Estevinho, M.M.(2)*;Catalano, G.(3);Patita, M.(4);Arroja, B.(5);Lago, P.(6);Rosa, I.(7);Tavares-de-Sousa, H.(8);Ministro, P.(9);Roseira, J.(8);Cancela, E.(9);Sousa, P.(9);Portela, F.(10);Correia, L.(11);Moreira, P.(12);Santiago, M.(13);Dias, S.(13);Afonso, J.(14);Danese, S.(15);Peyrin-Biroulet, L.(16);Dias, C.C.(17);
(1)Unit of Pharmacology and Therapeutics- Faculty of Medicine- University of Porto- Porto- Portugal., Department of Biomedicine-, Porto, Portugal;(2)Centro Hospitalar Vila Nova de Gaia/Espinho, Gastroenterology, Vila Nova de Gaia, Portugal;(3)Unit of Pharmacology and Therapeutics- Faculty of Medicine- University of Porto- Porto- Portugal, Biomedicine, Porto, Portugal;(4)Garcia da Orta Hospital- Almada- Portugal., Gastroenterology, Lisbon, Portugal;(5)Braga Hospital- Braga- Portugal., Gastroenterology, Braga, Portugal;(6)Porto Hospital University Centre- Porto- Portugal., Gastroenterology, Porto, Portugal;(7)IPOLFG- EPE- Lisbon- Portugal., Gastroenterology, Lisbon, Portugal;(8)Hospital Algarve, Gastroenterology, Portimão, Portugal;(9)Hospital Viseu, Gastroenterology, Viseu, Portugal;(10)Coimbra Hospital University Centre- Coimbra- Portugal., Gastroenterology, Coimbra, Portugal;(11)Northern Lisbon University Hospital Centre- Lisbon- Portugal, Gastroenterology, Lisbon, Portugal;(12)São João Hospital University Centre- Porto- Portugal., Clinical Pharmacology, Porto, Portugal;(13)Portuguese Group of Studies in Inflammatory Bowel Disease Grupo de Estudos da Doença Inflamatória Intestinal - GEDII- Portugal., a, Porto, Portugal;(14)Unit of Pharmacology and Therapeutics- Faculty of Medicine- University of Porto- Porto- Portugal., Biomedicine, Porto, Portugal;(15)IBD centre San Raffaelle, IBD centre, Milan, Italy;(16)Department of Gastroenterology and Inserm NGERE U1256- University Hospital of Nancy- University of Lorraine- Vandoeuvre-lès-- Nancy- France., Gastroenterology, Nancy, France;(17)Faculty of Medicine- University of Porto- Portugal., Information and Health Decision Sciences MEDCIDS-, Porto, Portugal;
P735: Real-life experience with the use of Tofacitinib in Colombian patients with moderate to severe Ulcerative Colitis: a descriptive study.ECCO’23 CopenhagenYear: 2023
Authors: Parra Izquierdo, L.V.(1)*;Frías-Ordoñez, J.(2); Márquez, J.R.(3);Juliao-Baños , F.(4);Galindo, P.(5);Cuadros, C.(6);Rojas, C.(7);Rojas, N.(7);Ardila, O.(8);Tovar-Fierro , G.(9);García-Duperly, R.(10);Gil Parada, F.L.(11);Imbeth Acosta, P.L.(12);Puentes, F.E.(13);Galiano de Sánchez, M.T.(14);Hani de Ardila, A.(15); Flórez-Sarmiento, C.(1);
(1)International Hospital of Colombia- Bucaramanga., Gastroenterology, Bucaramanga, Colombia;(2)National University of Colombia, Gastroenterology, Bogotá, Colombia;(3)Institute of Coloproctology- Las Américas Clinic- Medellín- Colombia, Gastroenterology, Medellin, Colombia;(4)Pablo Tobón Uribe Hospital- Medellín- Colombia, Gastroenterology, Medellin, Colombia;(5)Sebastián de Benalcázar Clinic- Cali- Colombia, Gastroenterology, Cali, Colombia;(6)International Hospital of Colombia- Bucaramanga., Pediatric Gastroenterology, Bucaramanga, Colombia;(7)Valle del Lili Foundation- Cali- Colombia, Gastroenterology, Cali, Colombia;(8)CES Clinic. Medellín- Colombia, Gastroenterology, Medellin, Colombia;(9)Carlos Ardila Lulle Foundation. Bucaramanga- Colombia., Gastroenterology, Bucaramanga, Colombia;(10)Santa Fe de Bogotá Foundation. Bogotá- Colombia, Coloproctology., Bogota, Colombia;(11)Colombia University Clinic- Bogotá., Gastroenterology and digestive endoscopy-, Bogota, Colombia;(12)Diagnosis and Therapeutics in Gastroenterology and Hepatology DITEG- Cartagena- Colombia, Gastroenterology, Cartagena, Colombia;(13)Unión de Cirujanos- Manizales- Caldas- Colombia, Gastroenterology, Manizales, Colombia;(14)Marly Clinic. Bogotá. Colombia, Gastroenterology, Bogota, Colombia;(15)Pontifical Xaverian University. Bogotá. Colombia, Gastroenterology, Bogota, Colombia;Colombian Crohn's and Colitis Study Group (GECCOL)
